Vericel Corporation (VCEL)
54.33
-3.45 (-5.97%)
At close: Feb 20, 2025, 3:59 PM
54.31
-0.04%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 46 |
| Market Cap | 2.68B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.08 |
| PE Ratio (ttm) | 679.13 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 59.49 |
| Volume | 252,976 |
| Avg. Volume (20D) | 377,608 |
| Open | 57.33 |
| Previous Close | 57.78 |
| Day's Range | 54.13 - 57.73 |
| 52-Week Range | 39.12 - 63.00 |
| Beta | undefined |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epic...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 1997
Employees 314
Stock Exchange NASDAQ
Ticker Symbol VCEL
Website https://vcel.com
Analyst Forecast
According to 6 analyst ratings, the average rating for VCEL stock is "Strong Buy." The 12-month stock price forecast is $65.5, which is an increase of 20.56% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Vericel Corporation is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.91%
Vericel shares are trading lower after the company...
Unlock content with
Pro Subscription
1 month ago
-1.59%
Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.
